Good Health Can’t Wait.

More documents

Recommendations

Info

Good Health Can’t Wait. Dr. Reddy’s Laboratories Limited ~3,000 TPA Potassium salt generated from evaporation processes, disposed to authorized recyclers to produce valuable fertilizers. The specific features of the three products are detailed below: Eslicarbazepine acetate Eslicarbazepine acetate is considered to be a second generation drug to oxacarbazepine and a third generation drug to carbamazepine, meant for treating epilepsy. As a pro drug to (S)-licarbazepine, Eslicarbazepine acetate is evolved in order to have improved efficacy and safety preventing the formation of toxic epoxide metabolite. Our previously reported synthesis involved a resolution strategy, which by design, yielded a maximum of 50% conversion. This process left behind almost the same quantity of material as waste, along with a significant quantity of liquid and solid effluents. We adopted an asymmetric reduction method, allowing for 80% yield. We also avoided a significant amount of waste. As a result, our manufacturing process has become energy efficient. Voriconazole Voriconazole has become the new standard of care in the treatment of invasive aspergillosis. This condition may occur in immunocompromised patients, including allogeneic BMT, hematologic cancers and solid organ transplants. Our previously reported synthesis involved a resolution strategy, which by design, yielded a maximum of 50% conversion. This process left behind almost the same quantity of material as waste, along with a significant quantity of liquid and solid effluents. We adopted the diastereoselcetive coupling method, allowing for relatively higher yields and selectivity. Eventually, a significant amount of waste was avoided, making the manufacturing process more energy efficient. Pregabalin (S)-3-(Aminomethyl)-5-methylhexanoic acid ((S)-Pregabalin) is a 4-aminobutyric acid (GABA) analogue. Our Pregabalin is used as an anticonvulsant drug to treat epilepsy, anxiety and social phobia. Our previously reported synthesis involved a resolution strategy, which by design, yielded a maximum of 50% conversion. This process left behind almost the same quantity of material as waste, along with a significant quantity of liquid and solid effluents. We outsourced the advanced intermediate, considering the recycling of undesired enantiomer, recovery of solvents and resolving agents at our vendor’s site. As a result, a significant amount of waste has been avoided, making the overall manufacturing process more energy efficient. 3. Does the company have procedures in place for sustainable sourcing (including transportation)? If yes, what percentage of your inputs was sourced sustainably? Also, provide details thereof, in about 50 words or so. At Dr. Reddy’s, we have a well-defined and documented ‘Supplier Code of Conduct’, addressing various aspects of sourcing, in addition to ethics, labor and human rights, wages and benefits, health and safety, environment and management systems including bribery and corruption. We have dedicated resources involved in building capacity and sharing best practices among all our strategic business partners (Total no.: 450). We are developing alternate reliable vendors, especially wherever we have single vendors to ensure business continuity. We are ensuring that our efforts and processes align with our targets of reducing air shipments from the current 60% to 40%. 4. Has the company taken any steps to procure goods and services from local & small producers, including communities surrounding their place of work? If yes, what steps have been taken to improve their capacity and capability of local and small vendors? We have procedures in place to procure goods and services from local, as well as small producers. At present, 60% of our procurements are sourced from domestic producers and the rest from international producers. We have dedicated resources assigned to the job of improving capacity and capabilities of local producers. Some of 32
Statutory Reports • Business Responsibility Report Annual Report 2014 - 15 Quality Control lab in Bristol 3,073 women employees As on 31 March 2015. our initiatives in this area include: Imparting mandatory supplier trainings for new vendors; Sharing good practices through audits and workshops; Reworking packaging design to reduce carbon footprint; and Inculcating a culture of resource conservation among local and small producers. Additionally, we improved solvent recovery efficiencies and eliminated the use of hazardous solvents like Methylene Dichloride. 5. Does the company have a mechanism to recycle products and waste? If yes what is the percentage of recycling of products and waste (separately as 10%). Also, provide details thereof, in about 50 words or so. Yes, we do have a mechanism to recycle products and waste. We practice the alternate reuse of potassium salts in our CTO (Chemical Technical Operations). Nearly 3,000 TPA of potassium salt, generated from evaporation processes, is disposed to authorized recyclers to produce valuable fertilizers. Potash is reprocessed by a recycler and 2,000 TPA of potassium salt is produced on a dry basis. Of the 2,000 TPA potassium salt produced, 800 T of chloride-free salt is used for the cultivation on 4,000 acres. About 400 T is sold as fertilizer for horticulture crops like palm oil, cocoa, coconut, sugarcane and more, covering 4,000 acres. The balance 800 T is given to the oil drilling sector, which enables savings in foreign exchange. These initiatives have helped us minimize the hazardous waste to landfill, by completely reusing the salts with an annual savings of ` 84 lakhs. We also reuse waste at our Formulation Technical Operations (FTOs). During the year, we commissioned an ETP Sludge dewatering facility, which 33
Page 1 and 2: ANNUAL REPORT 2014-15 Good Health C
Page 3 and 4: Our Brand We are in the business of
Page 5 and 6: Corporate Overview Annual Report 20
Page 29 and 30: Statutory Reports • Business Resp
Page 33: Statutory Reports • Business Resp
Page 43 and 44: Statutory Reports • Management Di
Page 57 and 58: Statutory Reports • Corporate Gov
Page 73 and 74: Statutory Reports • Additional Sh
Page 85 and 86:
Statutory Reports • Additional Sh
Page 87 and 88:
Statutory Reports • Board’s Rep
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Standalone Financial Statements Ann
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
Page 163 and 164:
Page 165 and 166:
Consolidated Financial Statements A
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
Page 173 and 174:
Page 175 and 176:
Page 177 and 178:
Page 179 and 180:
Page 181 and 182:
Page 183 and 184:
Page 185 and 186:
Page 187 and 188:
Page 189 and 190:
Page 191 and 192:
Page 193 and 194:
Page 195 and 196:
Page 197 and 198:
Page 199 and 200:
Page 201 and 202:
Page 203 and 204:
Page 205 and 206:
Page 207 and 208:
Page 209 and 210:
Page 211 and 212:
Page 213 and 214:
Page 215 and 216:
Page 217 and 218:
Page 219 and 220:
Page 221 and 222:
Page 223 and 224:
Page 225 and 226:
Page 227 and 228:
Notice Annual Report 2014 - 15 NOTI
Page 229 and 230:
E-Voting Annual Report 2014 - 15 IN
Page 231:
Dr. Reddy’s Laboratories Limited
Page 235 and 236:
The future belongs, not to those wh
show all

Good Health Can’t Wait.

Create successful ePaper yourself

Delete template?

Save as template?